PeptideDB

BA-53038B 2306195-65-1

BA-53038B 2306195-65-1

CAS No.: 2306195-65-1

BA-53038B (BA53038B)is a novel and potent Hepatitis B Virus Nucleocapsid Assembly Inhibitor, also called HBV core protei
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

BA-53038B (BA53038B)is a novel and potent Hepatitis B Virus Nucleocapsid Assembly Inhibitor, also called HBV core protein allosteric modulator (CpAM). It acts by binding to the HAP pocket and modulating HBV capsid assembly in a distinct manner, with an EC50 value of 3.32 μM.


Physicochemical Properties


Molecular Formula C14H16CLNO
Molecular Weight 249.735942840576
Exact Mass 249.092
CAS # 2306195-65-1
PubChem CID 138454763
Appearance White to off-white solid powder
LogP 3.9
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 1
Rotatable Bond Count 2
Heavy Atom Count 17
Complexity 295
Defined Atom Stereocenter Count 0
SMILES

ClC1=CC=CC(=C1)NC(C1C2CCCCC21)=O

InChi Key ZLCICHYECNOTGG-UHFFFAOYSA-N
InChi Code

InChI=1S/C14H16ClNO/c15-9-4-3-5-10(8-9)16-14(17)13-11-6-1-2-7-12(11)13/h3-5,8,11-13H,1-2,6-7H2,(H,16,17)
Chemical Name

N-(3-chlorophenyl)bicyclo[4.1.0]heptane-7-carboxamide
Synonyms

BA-53038B; AKOS040732521; MS-23535; HY-114314; CS-0082064;
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro BA-53038B exhibits anti-HBV action, as evidenced by its EC50 value of 3.32 μM [1]. BA-53038B exhibits cytotoxicity, as evidenced by a CC50 value greater than 100 μM [1]. Reduced amounts of hypophosphorylated core protein and alterations in capsid/nucleocapsid mobility are caused by BA-53038B (5 μM; 48 hours) [1]. HBV nucleocapsid assembly is inhibited by BA-53038B (0–20 μM; 2 or 6 days) [1]. Reduces the quantity of hypophosphorylated core protein and DNA-containing capsid by inhibiting pgRNA encapsidation (5 μM; 2 days) [1]. By attaching to the HAP pocket, BA-53038B (2 μM; 6 hours) modifies the assembly of HBV capsids [1]. HepG2 cells transfected transiently with pHBV1.3/core-V124W exhibit resistance to HBV capsid with an EC50 value >10 μM against BA-53038B [1].
Cell Assay Western Blot analysis [1]
Cell Types: AML12HBV10 Cell
Tested Concentrations: 5 μM
Incubation Duration: 48 h
Experimental Results: The amount of low-phosphorylated core protein is diminished, which promotes the assembly of empty capsids and slows the electrophoretic mobility.

RT-PCR[1]
Cell Types: AML12HBV10 and HepDES19 cells
Tested Concentrations: 0-20 μM
Incubation Duration: 2 or 6 days
Experimental Results: Inhibition of HBV replication in AML12HBV10 and HepDES19 cells.
References

[1]. Discovery of Novel Hepatitis B Virus Nucleocapsid Assembly Inhibitors. ACS Infect Dis. 2019 May 10;5(5):759-768.


Solubility Data


Solubility (In Vitro) DMSO : ~250 mg/mL (~1001.04 mM)
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 4.0042 mL 20.0208 mL 40.0416 mL
5 mM 0.8008 mL 4.0042 mL 8.0083 mL
10 mM 0.4004 mL 2.0021 mL 4.0042 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.